Hospital alert to prescribe rivaroxaban to prevent blood clots
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether alerting your hospital doctor to prescribe a blood thinner called rivaroxaban (Xarelto) at discharge can help prevent dangerous blood clots in your legs or lungs. It is for patients who are at higher risk for clots but have a low bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are currently in the hospital and being discharged home.
- You have a low risk of bleeding (as assessed by your doctor).
- You are not already taking a blood thinner like apixaban, rivaroxaban, or warfarin.
- Your kidney function is good (creatinine clearance above 30).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood thinners (rivaroxaban pills versus LMWH shots) to see which is better at preventing blood clots in people with leg injuries that require a cast or brace. If you qualify, you can receive one of these treatments while your leg heals.
This trial checks if patients leaving the emergency room or short-stay units while on a blood thinner (anticoagulant) have a higher chance of bleeding or clotting problems. It aims to help doctors give better advice to prevent these issues.
This trial tests a computerized tool that helps doctors decide who needs prevention medicines to lower the risk of blood clots after a hospital stay. It may help reduce preventable clotting risk for people who are less mobile and have added risk factors.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial tests a blood thinner called rivaroxaban (Xarelto) given right after heart valve surgery with a tissue valve. It aims to see if it can prevent blood clots or strokes safely in the early recovery period.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
Hear when a new Venous Thromboembolic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.